First Tracks Biotherapeutics (NASDAQ:TRAX) Posts Quarterly Earnings Results, Misses Estimates By $0.21 EPS
by Amy Steele · The Cerbat GemFirst Tracks Biotherapeutics (NASDAQ:TRAX – Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.21), Zacks reports.
First Tracks Biotherapeutics Stock Down 1.3%
TRAX traded down $0.62 during trading on Wednesday, reaching $46.13. The stock had a trading volume of 405,495 shares, compared to its average volume of 639,342. The stock has a 50 day simple moving average of $29.33. The stock has a market cap of $1.61 billion and a price-to-earnings ratio of -25.07. First Tracks Biotherapeutics has a 1-year low of $14.72 and a 1-year high of $49.91.
Analyst Ratings Changes
Several analysts have weighed in on the company. Piper Sandler started coverage on First Tracks Biotherapeutics in a research note on Monday, May 4th. They set an “overweight” rating and a $54.00 target price on the stock. UBS Group raised their price target on First Tracks Biotherapeutics from $45.00 to $65.00 and gave the company a “buy” rating in a report on Monday. JPMorgan Chase & Co. assumed coverage on shares of First Tracks Biotherapeutics in a research note on Thursday, April 23rd. They set an “overweight” rating and a $31.00 price objective on the stock. Wedbush upped their price objective on shares of First Tracks Biotherapeutics from $30.00 to $60.00 and gave the stock an “outperform” rating in a report on Tuesday, July 28th. Finally, Wall Street Zen upgraded shares of First Tracks Biotherapeutics to a “hold” rating in a research report on Saturday, May 2nd. Eight equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $50.38.
View Our Latest Research Report on First Tracks Biotherapeutics
First Tracks Biotherapeutics Company Profile
First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies which modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033 and ANB101. First Tracks Biotherapeutics is based in SAN DIEGO.